REPLIGEN CORP Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
REPLIGEN CORP (RGEN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 614.00 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-07-29
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 614.00K shares, a 6.12% decline year-over-year.
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 520.00K shares, a 27.14% increase year-over-year.
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 652.93K shares, a 32.92% increase year-over-year.
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 654.00K shares, a 36.40% increase year-over-year.
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 449.73K shares, a 6.54% increase from fiscal 2024.
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 422.13K shares, a 37.57% increase from fiscal 2023.
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 306.85K shares, a 73.05% increase from fiscal 2022.
- REPLIGEN CORP antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 177.32K shares, a 157.10% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 614.00K shares 10-Q · filed 2026-07-29 | 576.00K shares 10-Q · filed 2026-07-29 | |||||
| 2026-03-31 | 520.00K shares 10-Q · filed 2026-05-06 | ||||||
| 2025-12-31 | 449.73K shares 10-K · filed 2026-02-26 | ||||||
| 2025-09-30 | 652.93K shares 10-Q · filed 2025-11-04 | 610.88K shares 10-Q · filed 2025-11-04 | |||||
| 2025-06-30 | 654.00K shares 10-Q · filed 2026-07-29 | 654.01K shares 10-Q · filed 2025-08-07 | 605.00K shares 10-Q · filed 2026-07-29 | 604.97K shares 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 409.00K shares 10-Q · filed 2026-05-06 | 409.41K shares 10-Q · filed 2025-04-29 | |||||
| 2024-12-31 | 422.13K shares 10-K · filed 2026-02-26 | ||||||
| 2024-09-30 | 491.21K shares 10-Q · filed 2025-11-04 | 404.99K shares 10-Q · filed 2025-11-04 | |||||
| 2024-06-30 | 479.48K shares 10-Q · filed 2025-08-07 | 358.63K shares 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | 299.00K shares 10-Q · filed 2025-04-29 | ||||||
| 2023-12-31 | 306.85K shares 10-K · filed 2026-02-26 | ||||||
| 2023-09-30 | 301.40K shares 10-Q/A · filed 2024-11-18 | 328.18K shares 10-Q/A · filed 2024-11-18 | |||||
| 2023-06-30 | 456.31K shares 10-Q/A · filed 2024-11-18 | 400.91K shares 10-Q/A · filed 2024-11-18 | |||||
| 2023-03-31 | 263.87K shares 10-Q/A · filed 2024-11-18 | ||||||
| 2022-12-31 | 177.32K shares 10-K · filed 2025-03-14 | ||||||
| 2022-09-30 | 112.18K shares 10-Q/A · filed 2024-11-18 | 149.19K shares 10-Q/A · filed 2024-11-18 | |||||
| 2022-06-30 | 325.69K shares 10-Q/A · filed 2024-11-18 | 306.40K shares 10-Q/A · filed 2024-11-18 | |||||
| 2022-03-31 | 137.25K shares 10-Q/A · filed 2024-11-18 | ||||||
| 2021-12-31 | 68.97K shares 10-K/A · filed 2024-11-18 | ||||||
| 2021-09-30 | 44.91K shares 10-Q · filed 2022-11-01 | 63.77K shares 10-Q · filed 2022-11-01 | |||||
| 2021-06-30 | 69.39K shares 10-Q · filed 2022-08-02 | 69.39K shares 10-Q · filed 2022-08-02 | |||||
| 2021-03-31 | 94.24K shares 10-Q · filed 2021-05-04 | ||||||
| 2020-12-31 | 98.05K shares 10-K · filed 2023-02-22 | ||||||
| 2020-09-30 | 60.20K shares 10-Q · filed 2021-10-28 | 117.16K shares 10-Q · filed 2021-10-28 | |||||
| 2020-06-30 | 11.58K shares 10-Q · filed 2021-07-27 | 12.33K shares 10-Q · filed 2021-07-27 | |||||
| 2020-03-31 | 39.71K shares 10-Q · filed 2021-05-04 | ||||||
| 2019-12-31 | 104.32K shares 10-K · filed 2022-02-17 | ||||||
| 2019-09-30 | 47.70K shares 10-Q · filed 2020-11-05 | 85.50K shares 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | 119.03K shares 10-Q · filed 2020-07-30 | 180.16K shares 10-Q · filed 2020-07-30 | |||||
| 2019-03-31 | 210.39K shares 10-Q · filed 2020-05-06 | ||||||
| 2018-12-31 | 479.85K shares 10-K · filed 2020-02-26 | ||||||
| 2018-09-30 | 329.41K shares 10-Q · filed 2019-10-31 | 485.52K shares 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | 551.01K shares 10-Q · filed 2019-08-01 | 615.93K shares 10-Q · filed 2019-08-01 | |||||
| 2018-03-31 | 593.87K shares 10-Q · filed 2019-05-09 | ||||||
| 2017-12-31 | 479.85K shares 10-K · filed 2021-02-24 | 317.92K shares 10-K · filed 2018-02-22 | |||||
| 2017-09-30 | 162.54K shares 10-Q · filed 2018-11-01 | 326.57K shares 10-Q · filed 2018-11-01 | |||||
| 2017-06-30 | 187.07K shares 10-Q · filed 2018-08-02 | 222.00K shares 10-Q · filed 2018-08-02 | |||||
| 2017-03-31 | 458.69K shares 10-Q · filed 2018-05-08 | ||||||
| 2016-12-31 | 381.69K shares 10-K · filed 2019-03-01 | ||||||
| 2016-09-30 | 253.75K shares 10-Q · filed 2017-11-09 | 348.61K shares 10-Q · filed 2017-11-09 | |||||
| 2016-06-30 | 359.83K shares 10-Q · filed 2017-08-03 | 417.28K shares 10-Q · filed 2017-08-03 | |||||
| 2016-03-31 | 520.03K shares 10-Q · filed 2017-05-04 | ||||||
| 2015-12-31 | 196.21K shares 10-K · filed 2018-02-22 | ||||||
| 2015-09-30 | 163.46K shares 10-Q · filed 2016-11-03 | 170.89K shares 10-Q · filed 2016-11-03 | |||||
| 2015-06-30 | 126.54K shares 10-Q · filed 2016-08-04 | 150.04K shares 10-Q · filed 2016-08-04 | |||||
| 2015-03-31 | 199.58K shares 10-Q · filed 2016-05-05 | ||||||
| 2014-12-31 | 307.48K shares 10-K · filed 2017-02-23 | ||||||
| 2014-09-30 | 263.48K shares 10-Q · filed 2015-11-05 | 289.48K shares 10-Q · filed 2015-11-05 | |||||
| 2014-06-30 | 264.32K shares 10-Q · filed 2015-08-06 | 300.91K shares 10-Q · filed 2015-08-06 | |||||
| 2014-03-31 | 207.43K shares 10-Q · filed 2015-05-08 | ||||||
| 2013-12-31 | 187.00K shares 10-K · filed 2016-02-25 | ||||||
| 2013-09-30 | 161.00K shares 10-Q · filed 2014-11-07 | 469.50K shares 10-Q · filed 2014-11-07 | |||||
| 2013-06-30 | 520.55K shares 10-Q · filed 2014-08-11 | 540.55K shares 10-Q · filed 2014-08-11 | |||||
| 2013-03-31 | 516.50K shares 10-Q · filed 2014-05-09 | ||||||
| 2012-12-31 | 1.30M shares 10-K · filed 2015-03-17 | ||||||
| 2012-09-30 | 1.43M shares 10-Q · filed 2013-11-08 | 1.60M shares 10-Q · filed 2013-11-08 | |||||
| 2012-06-30 | 1.45M shares 10-Q · filed 2013-08-07 | 1.54M shares 10-Q · filed 2013-08-07 | |||||
| 2012-03-31 | 1.92M shares 10-Q · filed 2013-05-07 | ||||||
| 2011-12-31 | 2.82M shares 10-K · filed 2013-03-15 | ||||||
| 2011-09-30 | 2.05M shares 10-Q · filed 2012-11-08 | ||||||
| 2011-03-31 | 2.58M shares 10-K · filed 2013-03-15 | ||||||
| 2010-12-31 | 1.77M shares 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |